Becton, Dickinson and Company - US Medtechwert

Becton Dickinson fällt nach Senkung der Gewinnprognose

10. Feb. 2026

https://de.tradingview.com/news/reuters.com,2026:newsml_L8N3…

Becton, Dickinson and Company beruft Robert "Robbie" Huffines und Jacqueline "Jacky" Wright in den Vorstand, wirksam ab 1. Dezember 2025

Veröffentlicht am 17.11.2025 um 22:30

...

https://de.marketscreener.com/boerse-nachrichten/becton-dick…

Bevorstehender Unternehmenstermin

Bei Becton Dickinson steht morgen der Termin "Quartalsmitteilung" vor Öffnung an.
103 Nutzer haben Becton Dickinson im Portfolio und 214 unserer Nutzer haben Becton Dickinson auf der Watchlist.

Weitere Nachrichten zu Becton Dickinson finden Sie auf der Becton Dickinson Wertpapierdetailseite im Bereich "Neuigkeiten" und unter "Übersicht".
Eine Übersicht aller Unternehmenstermine finden Sie hier.

MACD Kaufsignal

aus dem Thread: Charts 2023 by Chartier

Entflechtung / Spin off

Hallo ist da jemand !
Diskussion über Becton, Dickinson ist ziemlich dürftig.
Habe in meinen Depot Embecta Corp. Aktien eingebucht bekommen.
Leider keine Diskussion darüber. Soll man die behalten oder nicht ?

Soll ein Isulin Spezialist sein.
Habe aufgerundet das heisst zugekauft.
In meinem Depot habe ich auch novo nordisk Aktien. Auch ein Insulin Spezialist.
Diese Papiere haben sich über die Jahre extrem gut entwickelt.

Gruss, und viel erfolg

Paul MacDonald discusses Becton Dickinson

https://www.bnnbloomberg.ca/video/paul-macdonald-discusses-b…

Paul Harris discusses Becton Dickinson

https://www.bnnbloomberg.ca/video/paul-harris-discusses-bect…

Jennifer Radman discusses Becton Dickinson

https://www.bnnbloomberg.ca/video/jennifer-radman-discusses-…

Gordon Reid discusses Becton Dickinson

https://www.bnnbloomberg.ca/video/gordon-reid-discusses-bect…

Hallo zusammen,

I'm back nach 12 jähren Pause an der Börse. Habe mich hier wieder freischalten lassen, werde aber nicht so aktiv sein wie früher...
Habe vor 2 Wochen eine erste Position gekauft.
Wer ist noch da, der mich kennt?
Gruß an alle!

Antwort auf 1435905 03.05.18 18:49:52 Uhr

08/02/2018 | 07:26am EDT
By Nishant Mohan
Becton, Dickinson and Co. (BDX) posted its first profit for the year on Thursday, beating analyst expectations for per-share earnings in the third quarter.
The medical technology company reported third-quarter net income of $556 million, compared with a loss of $165 million a year ago.
Adjusting for the costs of its acquisitions of C. R. Bard Inc. and CareFusion Corp. and other charges, the company reported per-share earnings of $2.91 compared with $2.46 a year ago and beating a $2.86 consensus estimate from analysts polled by FactSet.
The company's revenue rose 41% to $4.28 billion.
The company narrowed its guidance for the year, now expecting year-over-year growth of 31.5% compared with previous guidance predicting 31% to 31.5%
Shares of the company are up 16.8% to $250 a share so far this year.
Write to Nishant Mohan at [e-mail]

http://www.4-traders.com/BECTON-DICKINSON-AND-COM-11801/news…

Antwort auf 1435905 03.05.18 18:45:04 Uhr

Die Zahlen waren gut, der Ausblick wurde leicht angehoben.
Der Kurs ist heute in ein mittleres rot getaucht (z.Z. 189€)
Vielleicht hatte der ein oder andere auf mehr spekuliert oder es sind schlicht Gewinnmitnahmen.

BD Raises FY18 Guidance

Becton, Dickinson and Company (BDX) increased its fiscal 2018 adjusted earnings per share guidance to be between $10.90 and $11.05 due to an increase in the estimated benefit from foreign currency. This represents growth of approximately 15.0 to 16.5 percent over fiscal 2017 adjusted diluted earnings per share, and is an increase from previous guidance of $10.85 to $11.00 which represented growth of approximately 15.0 to 16.0 percent. On a currency-neutral basis, the company continues to expect full fiscal year adjusted earnings per share growth of approximately 12.0 percent.

The company now expects fiscal 2018 revenues to increase approximately 31.0 to 31.5 percent on a reported basis. This is an improvement from previously issued guidance of 30.0 to 31.0 percent growth. On a comparable, currency-neutral basis, the company raised its revenue guidance to 5.0 to 5.5 percent growth, which is the high end of its previous guidance range. 

Second-quarter adjusted earnings per share were $2.65, compared with $2.30 in the prior-year period. This represents an increase in adjusted earnings per share of 15.2 percent, or 7.8 percent on a currency-neutral basis. Revenues of $4.222 billion, represents an increase of 42.2 percent from the prior-year period, which is primarily due to the acquisition of C. R. Bard. On a comparable, currency-neutral basis that includes the revenues of C.R. Bard in the current and prior year, revenues increased 5.7 percent over the prior-year period.

Quelle: dpa-AFX vom 03.05.2018

BD Sees Adj. Earnings In Line With Market View, Higher Revenues In FY18

Becton, Dickinson and Co. or BD (BDX), a medical technology company, on Tuesday said it expects fiscal 2018 adjusted earnings per share to be between $10.85 and $11.00 on a stand-alone basis. The outlook represents growth of about 15.0 to 16.0 percent, or about 12.0 percent on a currency-neutral basis, over fiscal 2017 adjusted earnings per share of $9.48. This includes the accretion from the C.R. Bard acquisition.

The company had earlier projected fiscal 2018 adjusted earnings per share to be between $10.55 and $10.65 on a stand-alone basis.

On average, 15 analysts polled by Thomson Reuters expect earnings of $10.88 per share for the year. Analysts' estimates typically exclude special items.

The company expects full year 2018 revenues, including the accretion from the acquisition of C.R. Bard, to increase 30.0 to 31.0 percent as reported, or 4.5 to 5.5 percent on a currency-neutral basis.

This includes an estimated 50 basis point adverse impact from the change in the U.S. dispensing business model and the estimated sales impact from Hurricane Maria in Puerto Rico on Bard's business during BD's first fiscal quarter.

The company earlier expected full year 2018 revenues to increase 5 to 6 percent as reported, or 4 to 5 percent on a currency-neutral basis, including an estimated 50 basis point adverse impact from the change in the U.S. dispensing business model.

Analysts expect revenues of $15.87 billion for the new year. In 2017, the company recorded $12.09 billion revenues.

Quelle: dpa-AFX vom 06.02.2018

BD Sees Adj. Earnings Above Market View, Higher Revenues In FY18

Becton, Dickinson and Co. or BD (BDX), a medical technology company, on Thursday said it expects fiscal 2018 adjusted earnings per share to be between $10.55 and $10.65 on a stand-alone basis. The outlook represents growth of approximately 12 percent over fiscal 2017 adjusted earnings per share of $9.48.

On average, 16 analysts polled by Thomson Reuters expect earnings of $9.46 per share for the year. Analysts' estimates typically exclude special items.

On a stand-alone basis, the company expects full year 2018 revenues to increase 5 to 6 percent as reported, or 4 to 5 percent on a currency-neutral basis, including an estimated 50 basis point adverse impact from the change in the U.S. dispensing business model.

Analysts expect revenues of $12.07 billion for the new year. In 2017, the company recorded $12.09 billion revenues.

Further, the company said the acquisition of C.R. Bard is on-track with an expected closing date in the fourth calendar quarter of 2017, subject to certain regulatory approvals and other customary closing conditions.

Guidance inclusive of the C.R. Bard acquisition will be provided after the close of the transaction.

Vincent Forlenza, Chairman and CEO, said, 'We are very pleased with our strong fourth quarter and fiscal 2017 results. . We enter fiscal 2018 with continued momentum in our core and look forward to the successful closing of the C.R. Bard acquisition.'

Quelle: dpa-AFX vom 02.11.2017

BD Raises 2017 Adj. Earnings Guidance

Becton, Dickinson and Company (BDX) announced, on a currency-neutral basis, the company continues to expect fiscal year adjusted earnings per share to be between $9.70 and $9.80. As a result of favorable foreign currency movement, the company raised its adjusted earnings per share guidance to be between $9.42 and $9.47. This is an increase from previous guidance of $9.35 to $9.45.

The company now expects fiscal 2017 revenues to decrease 3.0 to 3.5 percent, primarily due to the divestiture of the Respiratory Solutions business. This is an improvement from previously issued guidance of a 3.5 to 4.0 percent decrease in revenues and is due to a reduction in the estimated negative impact from foreign currency. The company continues to estimate that revenues for the fiscal 2017 will increase 4.5 to 5.0 percent on a comparable, currency-neutral basis that excludes Respiratory Solutions and other divestitures that closed in fiscal 2016.

Third-quarter adjusted earnings per share were $2.46, compared with $2.35 in the prior-year period. The company said this represents an increase of 4.7 percent, or 7.7 percent on a currency-neutral basis. BD reported quarterly revenues of $3.035 billion which represents a decrease of 5.1 percent from the prior-year period and is primarily due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, third quarter revenues grew 2.4 percent.

Quelle: dpa-AFX

Quartalszahlen

Becton, Dickinson and Company Reports 2% Rise In Q2 Bottom Line

Becton, Dickinson and Company (BDX) reported earnings for its second quarter that rose compared to the same period last year.

The company said its bottom line totaled $344 million, or $1.58 per share. This was up from $338 million, or $1.56 per share, in last year's second quarter.

Analysts had expected the company to earn $2.23 per share, according figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company said revenue for the quarter fell 3.3% to $2.97 billion. This was down from $3.07 billion last year.

Becton, Dickinson and Company earnings at a glance:

-Earnings (Q2): $344 Mln. vs. $338 Mln. last year. -Earnings Growth (Y-o-Y): 1.8% -EPS (Q2): $1.58 vs. $1.56 last year. -EPS Growth (Y-o-Y): 1.3% -Analysts Estimate: $2.23 -Revenue (Q2): $2.97 Bln vs. $3.07 Bln last year. -Revenue Change (Y-o-Y): -3.3%

-Guidance: Full year EPS guidance: $9.70 - $9.80

Quelle: dpa-AFX vom 02.05.2017

BDX kauft C R Bard

Becton Dickinson plant eine "kleine" 24-Mrd. Dollar-Übernahme:

http://www.wiwo.de/unternehmen/industrie/becton-dickinson-ka…

BD Updates FY17 Guidance

Becton, Dickinson and Company (BDX) announced, as reported, the company now expects full fiscal year earnings per share to be between $7.90 and $8.00. On a currency-neutral basis, the company is raising fiscal 2017 adjusted earnings per share to $9.70 to $9.80, an increase from previously issued guidance of $9.62 to $9.72. Including the incrementally negative estimated impact from foreign currency, the company now expects adjusted earnings per share to be between $9.35 and $9.45.

As reported, the company expects fiscal 2017 revenues to decrease 3.5 to 4.0 percent, primarily due to the divestiture of the Respiratory Solutions business. This is a reduction in previously issued guidance of a decrease of 3.0 to 3.5 percent due to the incrementally negative estimated impact from foreign currency. The company continues to estimate that revenues for the full fiscal year 2017 will increase 4.5 to 5.0 percent on a comparable, currency-neutral basis that excludes Respiratory Solutions and other divestitures that closed in fiscal year 2016.

As reported, earnings per share for the first quarter were $2.58, compared with $1.06 in the prior-year period. The company said this represents an increase of 143.4 percent and is primarily due to a litigation reserve reversal following a favorable appellate antitrust ruling. Adjusted earnings per share were $2.33, compared with $1.96 in the prior-year period.

BD reported quarterly revenues of $2.922 billion for the first fiscal quarter ended December 31, 2016. This represents a decrease of 2.1 percent from the prior-year period revenues due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, first quarter revenues grew 6.1 percent.

Quelle: dpa-AFX vom 02.02.2017

Becton Dickinson and Co. (BDX) Issues FY17 Earnings Guidance
November 3rd, 2016
Becton Dickinson and logoBecton Dickinson and Co. (NYSE:BDX) issued an update on its FY17 earnings guidance on Thursday morning. The company provided EPS guidance of $9.62-9.72 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.44. The company issued revenue guidance of (3.0%) – (3.5%) to ~$11.85-12.108 billion, compared to the consensus revenue estimate of $12.25 billion.

Shares of Becton Dickinson and Co. (NYSE:BDX) traded up 2.65% during midday trading on Thursday, hitting $171.30. 403,603 shares of the company were exchanged. Becton Dickinson and Co. has a 52-week low of $129.50 and a 52-week high of $181.76. The company has a 50-day moving average price of $174.26 and a 200-day moving average price of $171.13. The stock has a market capitalization of $36.47 billion, a price-to-earnings ratio of 32.69 and a beta of 1.04.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 3rd. The company reported $2.12 EPS for the quarter, beating the consensus estimate of $2.09 by $0.03. The company earned $3.23 billion during the quarter, compared to analysts’ expectations of $3.22 billion. Becton Dickinson and had a return on equity of 24.26% and a net margin of 9.24%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.94 EPS. On average, analysts forecast that Becton Dickinson and Co. will post $8.56 EPS for the current year.

A number of brokerages have recently issued reports on BDX. Argus reiterated a buy rating and set a $185.00 target price on shares of Becton Dickinson and in a report on Friday, October 21st. Citigroup Inc. cut Becton Dickinson and from a neutral rating to a sell rating and decreased their target price for the stock from $167.00 to $165.00 in a report on Friday, September 23rd. Cowen and Company restated an outperform rating and issued a $185.00 price target on shares of Becton Dickinson and in a report on Tuesday, August 16th. Leerink Swann restated a hold rating on shares of Becton Dickinson and in a report on Tuesday, August 9th. Finally, Jefferies Group restated a buy rating on shares of Becton Dickinson and in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $172.11.

In related news, insider Linda M. Tharby sold 11,704 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $177.27, for a total transaction of $2,074,768.08. Following the sale, the insider now directly owns 22,146 shares of the company’s stock, valued at approximately $3,925,821.42. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Gary M. Cohen sold 29,367 shares of the company’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $176.81, for a total value of $5,192,379.27. Following the sale, the insider now directly owns 125,870 shares in the company, valued at $22,255,074.70. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Foyston Gordon & Payne Inc increased its position in shares of Becton Dickinson and by 1.0% in the second quarter. Foyston Gordon & Payne Inc now owns 6,360 shares of the company’s stock worth $1,079,000 after buying an additional 60 shares during the last quarter. Public Sector Pension Investment Board increased its position in shares of Becton Dickinson and by 17.5% in the second quarter. Public Sector Pension Investment Board now owns 40,243 shares of the company’s stock worth $6,825,000 after buying an additional 6,000 shares during the last quarter. National Pension Service increased its position in shares of Becton Dickinson and by 15.9% in the second quarter. National Pension Service now owns 135,395 shares of the company’s stock worth $22,962,000 after buying an additional 18,546 shares during the last quarter. AXA increased its position in shares of Becton Dickinson and by 7.3% in the second quarter. AXA now owns 373,549 shares of the company’s stock worth $63,350,000 after buying an additional 25,542 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Becton Dickinson and by 1.7% in the second quarter. Alliancebernstein L.P. now owns 374,850 shares of the company’s stock worth $63,571,000 after buying an additional 6,266 shares during the last quarter. 82.30% of the stock is currently owned by institutional investors and hedge funds.

About Becton Dickinson

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Quelle ist https://www.thecerbatgem.com/2016/11/03/becton-dickinson-and…